Patient characteristics: table below summarizes the individual patient characteristics
| Patient | Age at start of P (y) | Stage at diagn-osis | Prior treatment before KI | PD-L1 status | KI | Time on KI alone (m) | Time on KI + P (m) | Change in target lesions and BOR on KI + P | PFS On KI + P (m) | OS from KI (m) | OS from KI+P (m) | Alive (A)/Deceased (D) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 56 | IVC | BC, CXRT | 5% | DT | 4.3 | 3.1 | 32% PD | 0.7 | 7.4 | 3.1 | D |
| 2 | 68 | IVC | BC | 30% | DT | 9.6 | 3.8 | 21% PD | 1.5 | 13.4 | 3.8 | D |
| 3 | 57 | IVB | Sg, CXRT | 80% | L | 1.9 | 6.9 | 19% PD | 1.5 | 8.9 | 6.9 | D |
| 4 | 58 | IVC | Sg, CXRT | 5% | DT | 26.2 | 13.9 | −7% SD | 0.6 | 40.1 | 13.9 | A |
| 5 | 60 | IVC | BC | 50% | L | 5.5 | 15.8 | −8% SD | 12.8 | 21.4 | 15.8 | A |
| 6 | 47 | IVB | Sg, CXRT | 60% | DT | 2.4 | 3 | −14% SD | 3 | 5.4 | 3 | D |
| 7 | 69 | IVC | CXRT | n/A | DT | 2 | 4.1 | −19% SD | 3.1 | 6.2 | 4.1 | D |
| 8 | 60 | IVC | SC, BC | > 95% | DT | 1.2 | 6.2 | −35% PR | 6.2 | 7.4 | 6.2 | A |
| 9 | 84 | IVC | Sg-Lobectomy | > 10% | L | 2.1 | 8.3 | −45% PR | 8.3 | 10.4 | 8.3 | D |
| 10 | 57 | IVC | SC, XRT | n/A | L | 2.4 | 16.1 | −47% PR | 13.1 | 18.5 | 16.1 | A |
| 11 | 73 | IVC | Sg, RAI | 20% | T | 3.7 | 4.9 | −48% PR | 2.6 | 6.7 | 4.9 | A |
| 12 | 76 | IVB | Sg, RAI | > 90% | L | 1.5 | 5 | −69% PR | 5 | 5.8 | 5 | D |
Sg Surgery, CXRT Chemoradiation, BC Bridging chemotherapy with paclitaxel with or without carboplatin while awaiting KI, SC Systemic cytotoxic chemotherapy, XRT external beam radiation, RAI radioactive iodine, DT dabrafenib+trametinib, L lenvatinib, T trametinib alone, w weeks, m months, y years, KI kinase inhibitor, BOR best overall response, PFS progression-free survival, OS overall survival, PD progressive disease, SD stable disease, PR, partial response